SeekingAlpha · Aug 10, 2026
Veracyte: Diagnostics With Favorable Economics
VCYT stock outlook: Decipher & Afirma show double-digit growth and improving margins, with Prosigna/TrueMRD upside.
VC
NASDAQ · VCYT
Veracyte, Inc.
Healthcare · Biotechnology
$45.25
Up+$0.96 (+2.17%)
Updated Aug 28, 2026, 6:40 AM
SID Score
5.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.34B
- P/E ratio
- 109.61
- Dividend yield
- 0.00%
- 52-week range
- $29.46 – $60.91
- Volume
- 1.33M
- Avg. volume
- 966.7K
Price performance
VCYT price history
1M range · 21 trading sessions · Daily adjusted prices
VCYT closed at $45.25 after 21 trading sessions, down 24.31% for the selected period.
- Last close
- $45.25
- Period change
- -24.31%
- Period low
- $40.68
- Period high
- $59.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $44.20 | $45.50 | $44.19 | $45.25 | 1.33M |
| Aug 26, 2026 | $43.78 | $44.52 | $43.25 | $44.29 | 2.18M |
| Aug 25, 2026 | $42.01 | $44.10 | $41.805 | $44.04 | 1.16M |
| Aug 24, 2026 | $42.00 | $42.067 | $41.02 | $41.47 | 1.17M |
| Aug 21, 2026 | $42.18 | $42.54 | $41.10 | $42.31 | 1.01M |
| Aug 20, 2026 | $41.67 | $42.445 | $41.05 | $41.79 | 980.36K |
| Aug 19, 2026 | $41.92 | $42.52 | $40.095 | $42.19 | 1.76M |
| Aug 18, 2026 | $41.80 | $42.35 | $40.35 | $40.68 | 1.14M |
| Aug 17, 2026 | $40.96 | $42.50 | $40.96 | $42.08 | 1.57M |
| Aug 14, 2026 | $42.54 | $43.125 | $41.00 | $41.25 | 1.67M |
| Aug 13, 2026 | $45.23 | $45.23 | $42.51 | $42.60 | 1.46M |
| Aug 12, 2026 | $46.545 | $46.76 | $44.28 | $44.68 | 874.12K |
| Aug 11, 2026 | $46.07 | $46.67 | $45.72 | $46.41 | 551.01K |
| Aug 10, 2026 | $46.87 | $47.75 | $46.12 | $46.27 | 761.91K |
| Aug 7, 2026 | $47.00 | $47.80 | $46.2101 | $47.22 | 821.47K |
| Aug 6, 2026 | $45.80 | $46.53 | $45.16 | $46.15 | 939.86K |
| Aug 5, 2026 | $46.07 | $47.96 | $45.92 | $46.15 | 1.23M |
| Aug 4, 2026 | $44.84 | $46.57 | $43.09 | $46.41 | 1.99M |
| Aug 3, 2026 | $46.36 | $47.32 | $44.805 | $44.85 | 2.01M |
| Jul 31, 2026 | $48.77 | $50.17 | $43.52 | $46.32 | 5.99M |
| Jul 30, 2026 | $55.36 | $59.96 | $54.73 | $59.78 | 1.55M |
Latest VCYT news
The latest Smart Investors Daily articles mentioning VCYT.
Stock researchCompany · Overview
VCYT research
Overview
Company profile and research snapshot.
Company profile
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $46.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Stephens & Co. | Overweight | — |
| Aug 4, 2026 | Morgan Stanley | Underweight | — |
| Aug 3, 2026 | Canaccord Genuity | Hold | — |
| Jul 31, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 9, 2026
Veracyte: Core Growth Funds Prosigna And TrueMRD
Veracyte (VCYT) Q2 2026 shows strong revenue/EBITDA growth, cash flow, and upside from Prosigna/TrueMRD. Explore valuation, moat, and guidance.
ChartMill · Aug 5, 2026
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential
Veracyte (VCYT) combines strong growth, reasonable valuation vs biotech peers, and solid profitability—an affordable growth candidate.
Benzinga · Aug 4, 2026
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $66 to $54.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
